Amyotrophic Lateral Sclerosis (ALS)

Welcome to the SGC-Karolinska side of ALS-RAP: the scientists, the screening, and the antibody selections

Posted onAuthorCarolyn MarksLeave a comment

Hello fellow scientists and open lab notebook readers! I’m Carolyn Marks and I’m working in the ALS-RAP partnership with Susanne Gräslund, who leads the Recombinant Antibodies Group at SGC-Karolinska in Stockholm, Sweden. SGC-Karolinska has had a long-standing collaboration with Helena Persson Lotsholm, Director of the Human Antibody Therapeutics Facility within the Drug Discovery and Development Read More …

Validated antibodies for ALS research: the ALS-RAP project

Posted onAuthorOpher GileadiLeave a comment

We are part of ALS-RAP, the ALS (Amyotrophic Lateral Sclerosis) Reproducible Antibody Platform. We’re addressing one of the big conundrums to biomedical research: the lack, or the poor quality, of many antibodies used for research ranging from cell biology to histopathology. ALS, also called MND (motor neurone disease), is a group of diseases that cause Read More …

Introducing the team: The Gileadi Group in Oxford.

Posted onAuthorOpher GileadiLeave a comment

Hi! I’m Opher Gileadi, I head a group at the Structural Genomics Consortium (SGC) in Oxford. For many years, we’ve been looking at proteins involved in human. We’ve looked at a wide variety of proteins: from DNA repair enzymes and transcription factors to enzymes involved in signalling. In most cases, we focus on early work: Read More …